Verily, a health technology company spun out of tech giant Alphabet, announced Wednesday that it is restructuring its management team and business and cutting 15% of its workforce.
According to a memo exclusively obtained by STAT, Amy Abernethy, the former Food and Drug Administration official that Verily brought on to advance the use of technology in speeding up clinical trials, will be elevated to president of product development and chief medical officer.
Verily also confirmed to STAT that co-founder and onetime chief medical officer, Jessica Mega, a longtime public face of the company, has left Verily. Vivian S. Lee, a radiologist and former health system executive who joined Verily in 2018 as president of health platforms, has also left the company.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect